Telos Capital Management Inc. Has $497,000 Position in Lam Research Co. (NASDAQ:LRCX)

Telos Capital Management Inc. raised its position in Lam Research Co. (NASDAQ:LRCX) by 31.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 634 shares of the semiconductor company’s stock after purchasing an additional 150 shares during the quarter. Telos Capital Management Inc.’s holdings in Lam Research were worth $497,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Valued Wealth Advisors LLC acquired a new position in Lam Research in the fourth quarter valued at about $30,000. Orion Capital Management LLC acquired a new position in Lam Research in the third quarter valued at about $25,000. BluePath Capital Management LLC acquired a new position in Lam Research in the third quarter valued at about $28,000. Asset Dedication LLC boosted its position in Lam Research by 56.7% in the third quarter. Asset Dedication LLC now owns 47 shares of the semiconductor company’s stock valued at $30,000 after buying an additional 17 shares in the last quarter. Finally, Rakuten Securities Inc. acquired a new position in Lam Research in the fourth quarter valued at about $38,000. 84.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on LRCX shares. Stifel Nicolaus boosted their price target on shares of Lam Research from $950.00 to $1,050.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC upped their target price on shares of Lam Research from $900.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Thursday. Susquehanna upped their target price on shares of Lam Research from $655.00 to $880.00 and gave the stock a “neutral” rating in a research report on Monday, January 29th. Mizuho upped their target price on shares of Lam Research from $900.00 to $935.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Finally, Evercore ISI started coverage on shares of Lam Research in a research report on Tuesday. They set an “outperform” rating and a $1,200.00 target price on the stock. Eight analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, Lam Research presently has a consensus rating of “Moderate Buy” and an average price target of $881.45.

Insider Buying and Selling at Lam Research

In other news, SVP Seshasayee Varadarajan sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $922.41, for a total value of $5,073,255.00. Following the completion of the transaction, the senior vice president now owns 22,095 shares in the company, valued at $20,380,648.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Seshasayee Varadarajan sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $922.41, for a total value of $5,073,255.00. Following the completion of the transaction, the senior vice president now owns 22,095 shares in the company, valued at $20,380,648.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Christina Corrreia sold 647 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $972.03, for a total transaction of $628,903.41. Following the completion of the transaction, the chief accounting officer now owns 5,541 shares of the company’s stock, valued at approximately $5,386,018.23. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,029 shares of company stock valued at $6,559,489. Corporate insiders own 0.32% of the company’s stock.

Lam Research Stock Down 5.3 %

Shares of NASDAQ:LRCX opened at $912.26 on Thursday. Lam Research Co. has a 52 week low of $482.74 and a 52 week high of $1,007.39. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.02 and a current ratio of 3.06. The company has a market capitalization of $119.60 billion, a PE ratio of 35.28, a PEG ratio of 3.49 and a beta of 1.51. The company has a 50 day moving average price of $945.78 and a two-hundred day moving average price of $797.54.

Lam Research (NASDAQ:LRCX) last issued its earnings results on Wednesday, January 24th. The semiconductor company reported $7.52 EPS for the quarter, beating the consensus estimate of $7.06 by $0.46. Lam Research had a net margin of 24.15% and a return on equity of 44.47%. The firm had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.71 billion. During the same quarter in the prior year, the firm earned $10.71 earnings per share. The business’s quarterly revenue was down 28.8% on a year-over-year basis. Analysts forecast that Lam Research Co. will post 28.9 earnings per share for the current year.

Lam Research Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 3rd. Shareholders of record on Wednesday, March 13th were paid a $2.00 dividend. This represents a $8.00 annualized dividend and a yield of 0.88%. The ex-dividend date was Tuesday, March 12th. Lam Research’s payout ratio is presently 30.94%.

Lam Research Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.